Pharma


  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip

    Merck sues to block Medicare negotiation of drug prices

    The drugmaker’s lawsuit claims the new pricing powers granted by the Inflation Reduction Act are unconstitutional and “tantamount to extortion.”

    By Updated 8 hours ago
  • Unlocking the Impact of Medical Affairs Overcoming Challenges in Defining and Measuring Success.
    Image attribution tooltip

    canva.com/Monkey Business Images

    Image attribution tooltip
    Sponsored by Acceleration Point

    Unlocking the impact of medical affairs: overcoming challenges in defining and measuring success

    Discover how medical affairs teams can overcome challenges to define and measure their impact, with a focus on KOL engagement, using a scientific journey approach and a comprehensive strategy.

    June 5, 2023
  • Single strand ribonucleic acid, RNA research Explore the Trendline
    Image attribution tooltip
    luismmolina via Getty Images
    Image attribution tooltip
    Trendline

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • A general view of the Pfizer Headquarters sign on November 10, 2020 in Tadworth, England.
    Image attribution tooltip
    Dan Kitwood via Getty Images
    Image attribution tooltip

    Pfizer says antibiotic is effective against tough-to-treat infections

    A drug the company acquired from AstraZeneca and developed for gram-negative infections — a growing public health threat — could be headed for a regulatory review later this year.

    By June 2, 2023
  • Corporate logos are seen outside  on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca abandons experimental bowel disease drug

    The drugmaker cited testing delays and an evolving “competitive landscape” in its decision to discontinue development of its IL-23 inhibitor brazikumab.

    By June 1, 2023
  • Customer in pharmacy holding medicine bottle
    Image attribution tooltip
    Tero Vesalainen via Getty Images
    Image attribution tooltip
    Sponsored by FedEx Office

    Racing to the finish line: help for reducing risks, ensuring security and driving faster speed-to-market

    When pharma manufacturers are racing to bring a new product to market, catastrophic printing errors and mislabeled materials can have a significant impact on timelines and budgets.

    May 22, 2023
  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical
    Image attribution tooltip

    Teva puts rival to Prometheus, Pfizer drugs at center of turnaround plans

    At an investor day, executives highlighted an experimental inflammatory disease drug targeting the protein TL1A as important to their long-term growth.

    By Updated May 19, 2023
  • The U.S. Supreme Court is seen in spring through the branches of a tree.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Supreme Court sides with Sanofi, Regeneron in patent fight with Amgen

    The court’s ruling could open the door for challenges to older classes of antibody therapies, said one legal expert, who added that it will give competitors “solace.” 

    By Updated May 18, 2023
  • Federal Trade Commission
    Image attribution tooltip
    Carol Highsmith. (2005). "The Apex Building" [Photo]. Retrieved from Wikimedia Commons.
    Image attribution tooltip

    On heels of Amgen lawsuit, FTC broadens investigation of PBMs

    The regulator is probing the business practices of two more drug purchasing organizations, deepening an investigation that began last year.

    By Kristin Jensen • May 18, 2023
  • A woman in business attire stands outside a conference room
    Image attribution tooltip
    Courtesy of Gilead
    Image attribution tooltip

    Gilead picks former Roche executive to run cell therapy unit Kite

    Cindy Perettie, the former Foundation Medicine CEO who most recently ran Roche’s molecular lab division, will follow Christi Shaw in the role. 

    By May 17, 2023
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip

    FTC sues to block Amgen’s $27.8B deal for Horizon

    The regulator’s challenge will test a more expansive view of how pharmaceutical mergers could harm consumers. Amgen remains confident it can complete the deal, however.

    By May 16, 2023
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi, AstraZeneca study results add support for their RSV drug in infants

    The antibody reduced RSV infections requiring hospitalization by 83% in a large study, bolstering evidence for the drug ahead of a U.S. approval decision later this year.

    By May 12, 2023
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Roche pays China-based biotech $70M for a new HER2 drug

    The drug, currently in Phase 1, is an oral medicine designed to cross the blood-brain barrier and better treat HER2 tumors that have spread to the brain.

    By May 9, 2023
  • A worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax in Berlin, Germany in February 2022.
    Image attribution tooltip
    Carsten Koall via Getty Images
    Image attribution tooltip

    Novavax cuts workforce by 25% as COVID vaccine sales fall

    The layoffs, which will affect hundreds of employees, are part of a major restructuring designed to reduce operational and research spending by as much as half.

    By May 9, 2023
  • Glass vials with orange caps sit on a pharmaceutical factory production line.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Catalent cuts outlook, delays results as it reveals new hurdles

    The pharmaceutical CDMO said it found “significant” issues with its forecasts over the past year, compounding manufacturing problems at three of its plants.

    By May 8, 2023
  • Pharmacist checking medicine on the rack
    Image attribution tooltip
    alvarez via Getty Images
    Image attribution tooltip
    Sponsored by FedEx Office

    Print can help you cut through misinformation

    Providing accurate information to protect patients from misinformation is a key goal for pharmaceutical companies, and print media can be a crucial part of the solution.

    May 8, 2023
  • A watershed of rivers beneath a sunrise.
    Image attribution tooltip
    Arctic-Images via Getty Images
    Image attribution tooltip
    Sponsored by ZS

    Pharma’s commercial model of tomorrow starts today

    Today’s commercial model cannot support pharma’s future. A new future calls for bold transformation.

    May 8, 2023
  • Image attribution tooltip
    Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo reveals another setback in obesity drug’s launch

    U.S. supply of Novo’s Wegovy will be “reduced temporarily,” while the Danish drugmaker gets a new contract manufacturer up and running, executives said.

    By May 4, 2023
  • A castor bean tick on a leaf
    Image attribution tooltip
    Erik Karits via Getty Images
    Image attribution tooltip

    Valneva, Pfizer push back timeline for Lyme disease vaccine

    After issues with a contract research group, the partners now expect to file an approval application for their shot in 2026, one year later than initially anticipated.

    By May 4, 2023
  • Johnson & Johnson band-aids are displayed on a table.
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    J&J spinoff Kenvue raises $3.8 billion in year’s largest IPO

    Separating out the consumer health division will leave J&J as a slimmed-down company focused on prescription drugs and medical devices.

    By Kristin Jensen • May 4, 2023
  • People walk past a building in New York City
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Lilly’s fortunes rise on back-to-back success for Alzheimer’s, obesity drugs

    At more than $400 billion, Lilly’s market value is nearing J&J’s despite the company earning less than one-third as much revenue. Strong data for medicines donanemab and Mounjaro are why. 

    By May 4, 2023
  • A sign for the Food and Drug Administration is seen on July 20, 2020 in Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip
    RSV vaccines

    FDA approves first RSV vaccine, clearing GSK’s Arexvy for older adults

    The decision represents the first fruits of a scientific breakthrough a decade ago that gave drugmakers, among them GSK, Pfizer and Moderna, a blueprint for an effective shot against the virus.

    By Updated May 3, 2023
  • A 3D illustration showing amyloid plaques in brain tissue
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip
    New Alzheimer's drugs

    Lilly drug slows Alzheimer’s decline in large study

    The company plans to quickly submit an application for U.S. approval based on the trial results, which showed a consistent benefit to treatment with the drug, called donanemab.

    By , Updated May 3, 2023
  • Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip

    Pfizer turns focus to new drugs as COVID vaccine revenue falls

    The drugmaker beat Wall Street’s first quarter forecasts despite a sales drop that puts pressure on it to succeed with upcoming market launches.

    By May 2, 2023
  • A general view of the Pfizer Headquarters sign on November 10, 2020 in Tadworth, England.
    Image attribution tooltip
    Dan Kitwood via Getty Images
    Image attribution tooltip

    FDA clears Pfizer’s pneumococcal vaccine for infants and children

    Pfizer’s latest Prevnar shot covers 20 strains of the virus, more than the 13 covered by its previous version and the 15 by Merck’s Vaxneuvance.

    By Updated May 3, 2023
  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip
    AbbVie
    Image attribution tooltip

    AbbVie weathers first months of biosimilar challenge to top-selling Humira

    While Humira sales declined, the drop was mostly due to price concessions AbbVie made to secure equal insurer access in the face of copycat competition.

    By April 28, 2023